Crohn's Disease

Patients diagnosed with inflammatory bowel disease in childhood attain a lower adult height than their peers without IBD, according to study results.

In this guest commentary, Anita Afzali, MD, medical director of the Inflammatory Bowel Disease Center at The Ohio State University Wexner Medical Center, discusses the highlights from the recent IBD Horizons conference held Feb. 29, in Columbus, Ohio.

Patients who adhere to health lifestyle choices, including those related to diet, exercise and smoking habits, had reduced mortality, according to study results.

As the concern about COVID-19 continues to spread, the entire medical community is on alert. Associations are cancelling or altering plans for scientific conferences, and institutions are implementing travel bans for faculty.

MAUI, Hawaii — Interleukin-23 inhibitors are effective for induction and maintenance of remission in Crohn’s disease and ulcerative colitis, according to an expert at the GUILD Conference 2020.

MAUI, Hawaii — Physicians should optimize and personalize the treatment algorithm for patients with inflammatory bowel disease, according to an expert at GUILD Conference 2020.

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of the subcutaneous formulation of Entyvio for maintenance therapy in adults with moderately to severely active ulcerative colitis or Crohn’s disease, according to a press release.

Acid-suppression medication may increase the risk for colonization with multidrug-resistant microorganisms. It was the top story in gastroenterology last week.

SCOTTSDALE, Ariz. — IL-23 drives IL-17 production. IL-17 inhibition is effective in ankylosing spondylitis. However, evidence has shown that IL-23 or IL-12/23 inhibition is not necessarily effective in AS.

Clinical and biological indices of disease activity improved in patients with Crohn’s disease when researchers shortened the Stelara 90 mg dose from every 8 weeks to every 4 weeks.